Evidence or study | Summary data | Limitations | |
Antimicrobial agents | Systematic review93 | Beneficial (see text) | |
Anti-inflammatories | *No data | ||
Mucolytics | |||
Bromhexine | Cochrane review101 | High doses of bromhexine with antibiotics eased difficulty in expectoration, reduction in sputum production | Not universally available |
rhDNase | Systematic review101 102 | No studies in acute phase.101 102 Note increased exacerbation rate when used in non-acute phase | Adverse effects more common in the group receiving rhDNase |
Airway clearance | |||
Chest physiotherapy | Cochrane review103 | No data* | |
Inhaled hyperosmolar agents | Cochrane review104 105 | One RCT using single mannitol dose in stable bronchiectasis,127 improved airway clearance; one study on 7% HS as adjunct to physiotherapy.105 Sputum weights, ease for expectoration, viscosity better in HS group | |
Asthma therapies | |||
Inhaled corticosteroids | No data during pulmonary exacerbation* | See table 2 for other data | |
Oral corticosteroids | Cochrane review106 | No RCTs | No other data* |
Anticholinergics | Cochrane review107 | No RCTs | No other data* |
β2 agonist | Cochrane review108 109 | No RCTs | No other data* |
LTRA | Cochrane review110 | No RCTs | No other data* |
Methylxanthines | Cochrane review128 | No RCTs | No other data* |
Exercise/physical training | No data* | ||
Oxygen | No data* | Consider data from COPD | |
Surgery | No data* | ||
Ventilatory assistance | |||
BTS guidelines126 | See text |
HS, hypertonic saline; LTRA, leucotriene receptor antagonist; RCT, randomised controlled trial; rhDNase, recombinant human deoxyribonuclease.
*No other data specific to acute exacerbation management based on single reviewer search (up to March 2006).